A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Clicks: 640
ID: 111036
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 41 articles by views in annals of the rheumatic diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity. CT-P13 was well tolerated, with a safety profile comparable with that of INX. CLINICALTRIALS.GOV IDENTIFIER: NCT01217086.
Reference Key
dh2013annalsa Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U
Are you one of these authors? Claim your profile
Journal annals of the rheumatic diseases
Year 2013
DOI
DOI not found
URL
https://www.pubmed.gov/23687260/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal / therapeutic use* Double-Blind Method Multicenter Study severity of illness index drug therapy combination pmid:23687260 pmc3786641 doi:10.1136/annrheumdis-2012-203090 dae hyun yoo pawel hrycaj ulf müller-ladner monoclonal / adverse effects monoclonal / blood antirheumatic agents / adverse effects antirheumatic agents / blood antirheumatic agents / therapeutic use* arthritis rheumatoid / blood rheumatoid / drug therapy* immunoglobulin g / adverse effects immunoglobulin g / blood immunoglobulin g / therapeutic use* infliximab methotrexate / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.